.

By STACY BIRNBACH

.

CBD is quickly emerging as a potential drug target for a variety of immune-mediated central nervous system diseases. CBD targets the endocannabinoid system (ECS), interacting with ECS's receptors and helping to restore homeostasis. The endocannabinoid system, discovered in the early 1990s by Dr. Raphael Mechoulam, the "father of cannabis research," is crucial to human health. The endocannabinoid system is a lipid signaling system, composed of "cannabis-like ligands," also known as endocannabinoids, including anandamide and 2-arachidonoylglycerol. These are Endogenous Cannabinoids that bind to cannabinoid receptors.

.

These endocannabinoids bind to a specific group of G-protein-coupled receptors (CB1 and CB2R). CB1 receptors are located in centers of the brain associated with motor control, emotional response, motivated behavior, and energy homeostasis. Secondary to areas of the brain, CB1 receptors can be found in tissues of the pancreas, liver, GI, skeletal muscle, heart and reproduction system. CB2 receptors mostly serve a regulatory purpose in the immune system. A number of health problems are attributed to ECS dysregulation, such as obesity, metabolic syndrome, and more. Additionally, it is important to note that endocannabinoids are receptor-dependent.

.

CBD is a safe and effective nutrient found in the hemp plant. CBD Oil and Hemp Oil both come from the same plant, the hemp plant. However, Hemp Oil typically comes from the seeds of the hemp plant, and thus does not contain the same quantity of cannabinoids found in CBD Oil or Hemp Extract, which are extracted from the entirety of the plant. Therefore, CBD Oil and Hemp Extract have more powerful medicinal effects. Unlike marijuana, CBD has no psychoactive effects. It is natural, non-toxic and has a favorable safety profile.

.

The medicinal effects of CBD come from it acting upon CB1 and CB2 receptors throughout the body. Some of the benefits of CBD activating CB1 receptors include relief from depression, lower intestinal inflammation, lower blood sugar, reduced anxiety, reduced fear and paranoia, and increased myelin formation. CBD also activates CB2 receptors which target a substantial number of diseases in the human body, including cardiovascular, gastrointestinal, neurodegenerative, psychiatric and autoimmune. For these reasons, according to the National Institute of Health, targeting the endocannabinoid system through external cannabinoids such as CBD could be useful in treating a number of ailments such as pain, epilepsy, multiple sclerosis, Parkinson, acne, psoriasis, ADHD, diabetes, schizophrenia, bacterial infections, substance abuse, withdrawal, and more.

.

CBD has the potential to vastly improve people's quality of life. In addition to the substantial research on CBD, testimonials have flooded the internet, attesting to its life-changing benefits. Because of CBD's notable medicinal effects, targeting a large variety of ailments, and its favorable safety profile, CBD should not be ignored. Not only does CBD offer promising health benefits for patients but additional revenue opportunities for those involved in the CBD market. The CBD product marketplace is global and rapidly growing. Initially, the Industrial Hemp Farming Act of 2015 excluded hemp from the Drug Enforcement Administration's controlled substances list, effectively legalizing and opening market opportunities for hemp-derived CBD products. President Trump's recent signing of the 2018 Farm Bill is thought to restore industrial hemp to nationwide legal production for the first time since World War II.

.

The total U.S. hemp industry now looks to expand at 18.4 percent rate through a 5-year combined annual growth rate (CAGR) from 2018-2022. Hemp Business Journal estimates that, in all leading hemp product categories, the hemp-derived CBD market will grow from a $390 million-dollar market in 2018 to a $1.3 billion market (3.3x) by 2022, representing a 27.2 percent, 5-year CAGR. For years, experts have predicted that if the cannabis industry expands at its current rate, the American market will reach $20 billion by 2020. But it is now estimated that the hemp-CBD market alone could reach $22 billion by 2022, and the overall market for Cannabis products could reach $80 Billion.

.

Considering these market statistics and the research on the benefits of CBD, offering CBD to patients, could provide an additional revenue stream for physicians as well as offer effective medicinal treatment. For instance, becoming a brand ambassador with a quality CBD company included in the PDR, could allow physicians to benefit from an additional CBD related revenue stream by promoting and recommending this safe and effective medication. If patients experience improvements from the recommended CBD products, then they will continue to purchase such products and as a result, the physicians will both be helping their patients and earning an additional revenue stream.

.

Patients who see results will additionally recommend the product to their family and friends, and as this network expands, so will the doctor's revenue stream, with minimal additional effort. Because of CBD's endocannabinoid target, making it an extremely exciting new treatment, and leading to the development of an expansive CBD product market, the CBD industry is especially valuable to doctors. It could potentially change lives both medically and financially.

.

Stacy Birnbach, a top executive recruiter and successful business woman, suffered from clinical bipolar depression for 30 years. After 3 decades of therapy and drugs, she cured herself naturally and discovered CBD, specifically Kannaway products, the only CBD company included in the PDR. Stacy, CEO and Founder of CBD for Total Health, started the company to educate people about the overall health benefits of CBD and the importance of using effective, quality products. For questions or more information, email Stacy at stacy@cbdfortotalhealth.com or visit https://www.cbdfortotalhealth.com/